FY2025 Earnings Forecast for VERA Issued By HC Wainwright

Vera Therapeutics, Inc. (NASDAQ:VERA) – HC Wainwright issued their FY2025 EPS estimates for Vera Therapeutics in a report released on Wednesday, March 5th. HC Wainwright analyst E. Arce forecasts that the company will earn ($2.40) per share for the year. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Vera Therapeutics’ FY2026 earnings at ($1.79) EPS.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.11.

Other equities analysts have also recently issued reports about the stock. Wedbush raised their target price on shares of Vera Therapeutics from $30.00 to $38.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. Guggenheim raised their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. The Goldman Sachs Group initiated coverage on shares of Vera Therapeutics in a research note on Tuesday, January 28th. They set a “buy” rating and a $58.00 target price for the company. JPMorgan Chase & Co. cut their target price on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating for the company in a research note on Tuesday. Finally, Wells Fargo & Company initiated coverage on shares of Vera Therapeutics in a research note on Thursday, November 21st. They set an “overweight” rating and a $70.00 target price for the company. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $64.67.

Vera Therapeutics Stock Performance

Shares of NASDAQ VERA opened at $29.30 on Friday. The firm has a fifty day moving average price of $34.70 and a 200-day moving average price of $40.07. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. The stock has a market cap of $1.86 billion, a PE ratio of -11.23 and a beta of 1.17. Vera Therapeutics has a 1 year low of $25.99 and a 1 year high of $51.61.

Institutional Investors Weigh In On Vera Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. bought a new stake in Vera Therapeutics during the 4th quarter valued at about $56,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Vera Therapeutics by 30.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 80,106 shares of the company’s stock valued at $3,388,000 after buying an additional 18,532 shares in the last quarter. Woodline Partners LP lifted its holdings in Vera Therapeutics by 20.1% during the 4th quarter. Woodline Partners LP now owns 1,202,466 shares of the company’s stock valued at $50,852,000 after buying an additional 201,573 shares in the last quarter. Vestal Point Capital LP bought a new stake in Vera Therapeutics during the 4th quarter valued at about $45,462,000. Finally, Thornburg Investment Management Inc. lifted its holdings in Vera Therapeutics by 91.1% during the 4th quarter. Thornburg Investment Management Inc. now owns 59,004 shares of the company’s stock valued at $2,495,000 after buying an additional 28,124 shares in the last quarter. Institutional investors own 99.21% of the company’s stock.

Insider Transactions at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 17,500 shares of the firm’s stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total value of $730,450.00. Following the completion of the sale, the chief executive officer now owns 143,603 shares in the company, valued at approximately $5,993,989.22. This trade represents a 10.86 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders sold 52,500 shares of company stock worth $2,305,625. 21.70% of the stock is currently owned by insiders.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.